We tested the sensitivity of the ICER of birth-cohort
screening with standard treatment compared with riskbased
(status quo) screening to univariate differences in
QALY losses; the discount rate; the probability of an SVR
for genotypes 1, 2, and 3; the proportion of virus that is
genotype 1; the cost of screening; and the costs of standard
treatment. We tested the sensitivity of the ICER of birthcohort
screening with DAA plus standard treatment compared
with standard treatment alone to univariate differences
in the costs and effectiveness of treatment.